Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
NCT05701774
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
83
Enrollment
INDUSTRY
Sponsor class
Conditions
Prader-Willi Syndrome
Interventions
DRUG:
DCCR
Sponsor
Soleno Therapeutics, Inc.